• Via Ritzau pressemeddelelser
  • Via Ritzau selskabsmeddelelser
  • Globenewswire
  • Business Wire
B. Braun Melsungen AG

B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®2.3.2021 15:48:50 CET | B. Braun Melsungen AG

Joint marketing of CytoSorb® with B. Braun’s newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients. MELSUNGEN, GERMANY and MONMOUTH JUNCTION, N.J., March 2, 2021 – B. Braun Avitum AG, a leading manufacturer of medical devices and pharmaceutical products and services and CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation, announce the launch of a global co-marketing agreement to promote the use of CytoSorb® with B. Braun’s latest OMNI® continuous blood purification platform and OMNIset® Plus bloodline set (set version 3.0 or higher). The CytoSorb® adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream and can be operated with the B. Braun OMNI® acute dialysis machine. B. Braun will supply the market with the OMNI®
  • 1
  • 2
  • 3
  • 4
  • 5
  • Sidste
  • >>